Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma

This study represents a phase I clinical trial that utilizes natural killer (NK) cell therapy for patients diagnosed with liver cancer, specifically those classified as Child-Pugh A and falling within the Barcelona Clinic Liver Cancer (BCLC) stages B or C. The expected results include determining the suitable treatment dosage, identifying any resulting side effects, and calculating the average duration of progression-free survival. The target group for the study consists of all individuals diagnosed with liver cancer. At the same time, the practical sample consists of those who received medica

Trial Details

NCT ID
NCT06044506
Phase
PHASE1
Sponsor
Dr Cipto Mangunkusumo General Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Autologous Natural Killer Cell Therapy
  • Clinimacs Plus
Locations (sample)
  • Jakarta Pusat, Jakarta Special Capital Region, Indonesia|-6.1818,106.8223

Key Eligibility Criteria

  • Patients aged 20-60 years old
  • Patients with Hepatocellular Carcinoma (HCC) staged as BCLC B and C
  • Karnofsky Performance Status (KPS) score ≥ 70
  • Expected patient survival of more than three months

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →